Enfusion, Inc. ENFN
Enfusion is a no-moat SaaS with tainted leadership, deteriorating unit economics, and revenue-reporting anomalies; Spruce Point sees 40-60% downside to $3.70-$5.60.
Thesis
Spruce Point is short Enfusion (NYSE: ENFN), arguing the investment-management SaaS provider faces extremely high financial-restatement risk behind a high-growth narrative. The entire C-suite — CEO, CFO, CRO and CSO — turned over in under two years, with several executives and the Audit Chair connected to firms previously sanctioned by the SEC or targeted by short-sellers (Ritchie Capital, Shift4, GE, Archer). Growing revenue paired with declining accounts receivable, a surreptitiously revised bad-debt allowance, ceased disclosure of Net Dollar Retention and client-mix metrics, collapsing Managed Services growth to under 1% QoQ, and a multi-year RPO that failed to grow all point to aggressive revenue recognition. Insider selling intensified, the credit facility was expanded 20x to $100m, and CEO Movchan enacted a 400,000-share 10b5-1 plan ahead of Investor Day. Applying 2.5x-3.5x EV/Sales yields a $3.70-$5.60 price target, implying 40-60% downside.
SCQA
Enfusion markets itself as a high-growth, cloud-native SaaS provider serving hedge funds and asset managers, with a rich 6x revenue multiple predicated on 15%+ growth and 'strength in numbers' disclosures.
The entire senior team has been replaced in two years — many with ties to SEC-sanctioned companies — while revenue grows, receivables fall, bad-debt allowance is quietly revised, and key retention metrics are being withdrawn from disclosure.
Investors should treat ENFN as a strong sell; the Audit Committee should investigate revenue recognition, restate disclosures of churn and RPO, and halt insider 10b5-1 sales ahead of Investor Day.
At a peer-justified 2.5x-3.5x EV/'24E revenue, Enfusion is worth $3.70-$5.60 per share versus the current ~$9.32 — approximately 40% to 60% downside risk.
The three reasons
- 1
CEO, CFO, CRO and CSO all replaced in 24 months, with ties to SEC-sanctioned firms
- 2
Revenue grew while A/R fell and bad-debt allowance was quietly revised — restatement risk
- 3
Contract terms, churn, and RPO all deteriorating behind retracted disclosures
Primary demands
- Audit Committee investigation of revenue reporting anomalies
- Restore disclosure of Net Dollar Retention, client counts, and contract term detail
- Explain unreconciled software capitalization and revised bad debt allowance
- Justify CEO 10b5-1 insider sale program ahead of Investor Day
KPIs cited
Pattern membership
Precedents cited
- Porch Group (PRCH) — prior Spruce Point short, -97%
- Perion Network (PERI) — prior Spruce Point short, -28%
- Lightspeed Commerce (LSPD) — prior Spruce Point short, -90%
- General Electric SEC $200M disclosure penalty (Audit Chair Jan Hauser was GE CAO 2013-2018)
- Shift4 Payments (FOUR) — prior short-activist accounting allegations (CFO Bradley Herring)
- Ritchie Capital Management SEC late-trading case (CEO Movchan was Director of Risk Management)
- Archer Aviation (ACHR) short-seller allegations (Board Chair Michael Spellacy)
Composition what's on the 29 slides
Slide gallery ·
Notes
Classic Spruce Point short-report structure: cinematic cover (rats + 'Error Alert. Revenue Reporting Issue!'), full legal disclaimer, track-record credibility slide, thesis summary, then forensic deep-dive into governance, disclosures, revenue recognition, cash flow, and valuation. Cover page lists presentation date indirectly — comp table prices are as of 3/13/2024 and the CEO's 10b5-1 begins 3/14/2024, supporting a mid-March 2024 publication. Explicit 'Strong Sell Opinion' on cover. Report leans heavily on disclosure-change comparisons (before/after language in filings), CEO quote contradictions on pricing power and Managed Services, and peer-gap EV/Sales and EBITDA-margin tables. Visual quality is solid institutional Spruce Point house style but not top-tier editorial.